As the Government announces a huge, pioneering project to sequence 100,000 genomes, Mark Henderson looks at what needs to happen to make the technique live up to its promise
A pioneering project to map 100,000 genomes will revolutionise medicine in Britain
A few years ago, I spat into three test tubes and dispatched them special delivery to companies that will now, for a few hundred pounds, test your genes for clues to your future health. Though each service examined the same DNA, and evaluated the same diseases, each set of results was dramatically different. My lifetime risk of glaucoma, an eye condition, was as low as 2 per cent or as high as 36 per cent, depending on which service I chose to believe. One company thought my chances of a heart attack were twice as high as another.
Mine was the sort of experience that has fed a growing sense that the sequencing of the human genome, heralded by Bill Clinton in 2000 as the future of medicine, has failed to deliver on its promise. While DNA has since become much cheaper and simpler to read – the cost of a human genome is dipping below the magical figure of $1,000 a time – its meaning remains devilishly difficult to interpret. As my results demonstrate, this is especially true of the conditions that are the greatest causes of morbidity and mortality – diabetes and heart disease, stroke and mental illness.
Mine was the sort of experience that has fed a growing sense that the sequencing of the human genome, heralded by Bill Clinton in 2000 as the future of medicine, has failed to deliver on its promise. While DNA has since become much cheaper and simpler to read – the cost of a human genome is dipping below the magical figure of $1,000 a time – its meaning remains devilishly difficult to interpret. As my results demonstrate, this is especially true of the conditions that are the greatest causes of morbidity and mortality – diabetes and heart disease, stroke and mental illness.